BIOMAT Database Logo BIOMAT Database Logo

A specific radioimmunoassay for insulin-like growth factor II: the interference of IGF binding proteins can be blocked by excess IGF-I. 1988

W F Blum, and M B Ranke, and J R Bierich
University Children's Hospital, Tübingen, FRG.

A specific antiserum for human IGF-II has been produced by immunizing rabbits against the synthetic peptide IGF-II(33-40). With this antiserum and IGF-II as tracer a radioimmunoassay for IGF-II has been developed. Cross-reactivity with IGF-I was 0.05% and half-maximal displacement occurred at 2.5 micrograms IGF-II per 1. It was demonstrated that residual IGF-binding protein (IGF-BP) in acid-ethanol extracts interferes with IGF-II measurements and may produce erroneously high values. This interference could be completely blocked by excess IGF-I (25 ng per tube). Utilizing this method IGF-II was measured in subjects at various developmental stages. In newborns, the mean serum level was 237 micrograms/l (N = 56) with a range of 132-430 micrograms/l (5- and 95-percentile, respectively). During the first year of life a considerable increase occurred. Thereafter IGF-II increased only slightly with age from 520 micrograms/l (range 368-735) to 647 micrograms/l (range 507-823) in adults. In patients with growth hormone deficiency (N = 57) IGF-II levels were significantly (P less than 0.001) lower than in controls (mean 261 micrograms/l, range 126-542). It is concluded 1) that residual IGF-binding proteins in acid-ethanol extracts may cause considerable error in IGF-II measurements, and 2) that this interference can be completely blocked by excess IGF-I, if highly specific antisera are used.

UI MeSH Term Description Entries
D007106 Immune Sera Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen. Antisera,Immune Serums,Sera, Immune,Serums, Immune
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D007335 Insulin-Like Growth Factor II A well-characterized neutral peptide believed to be secreted by the LIVER and to circulate in the BLOOD. It has growth-regulating, insulin-like and mitogenic activities. The growth factor has a major, but not absolute, dependence on SOMATOTROPIN. It is believed to be a major fetal growth factor in contrast to INSULIN-LIKE GROWTH FACTOR I, which is a major growth factor in adults. IGF-II,Multiplication-Stimulating Activity,Somatomedin MSA,IGF-2,Insulin Like Growth Factor II,Insulin-Like Somatomedin Peptide II,Multiplication-Stimulating Factor,Somatomedin A,Factor, Multiplication-Stimulating,Insulin Like Somatomedin Peptide II,Multiplication Stimulating Activity,Multiplication Stimulating Factor
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003429 Cross Reactions Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen. Cross Reaction,Reaction, Cross,Reactions, Cross

Related Publications

W F Blum, and M B Ranke, and J R Bierich
Radioimmunoassay for insulin-like growth factor (IGF) II: interference by pure IGF-binding proteins.
January 1990, Journal of immunoassay,
W F Blum, and M B Ranke, and J R Bierich
Quantification of insulin-like growth factor I (IGF-I) without interference by IGF binding proteins.
May 1997, Endocrinology,
W F Blum, and M B Ranke, and J R Bierich
Evaluation of interference by insulin-like growth factor I (IGF-I) binding proteins in a radioimmunoassay for IGF-I in serum from dairy cows.
July 1991, Domestic animal endocrinology,
W F Blum, and M B Ranke, and J R Bierich
Direct detection of insulin-like growth factor II (IGF-II) by chemiluminescence without interference by IGF binding proteins.
April 1994, Endocrinology,
W F Blum, and M B Ranke, and J R Bierich
Radioimmunoassay for insulin-like growth factor II (IGF-II).
October 1990, Endocrinologia japonica,
W F Blum, and M B Ranke, and J R Bierich
Radioimmunoassay for insulin-like growth factor I (IGF-I) using biosynthetic IGF-I.
December 1986, Endocrinologia japonica,
W F Blum, and M B Ranke, and J R Bierich
Insulin-like growth factor I (IGF-I), IGF-binding proteins, and breast cancer.
December 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology,
W F Blum, and M B Ranke, and J R Bierich
Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding proteins by tumor necrosis factor.
November 1995, The American journal of physiology,
W F Blum, and M B Ranke, and J R Bierich
Characterization of the affinities of insulin-like growth factor (IGF)-binding proteins 1-4 for IGF-I, IGF-II, IGF-I/insulin hybrid, and IGF-I analogs.
March 1993, Endocrinology,
W F Blum, and M B Ranke, and J R Bierich
Regulation of insulin-like growth factor-I (IGF-I) delivery by IGF binding proteins and receptors.
April 2006, Annals of biomedical engineering,
Copied contents to your clipboard!